Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases
Open Access
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 16
Abstract
Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody–drug conjugates (ADCs) has sparked a revolution in metastatic breast cancer (MBC) care. ADCs such as ado-trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan have demonstrated significant improvement in patient outcomes and are standard of care in the treatment of MBC. Most of the ADC registration studies included patients with stable BMs but excluded individuals with active BM, making intracranial (IC) response assessment a challenge. Promising data has recently emerged, suggesting relevant IC activity for certain ADCs and ongoing studies in patients with active BM that will expand our knowledge. This review aims to summarize the effectiveness of approved ADCs as well as promising new ADCs in development for breast cancer with BM.Keywords
Funding Information
- PT discloses research funding (to institution) from AstraZeneca and consulting/advisory role for Daiichi Sankyo, Astra Zeneca, Eli Lilly, Gilead Sciences, Genentech/Roche
- SS discloses: Consulting fees from Foundation Medicine, Astra Zeneca, Daichii Sankyo, Eli Lilly, Pfizer, Incyclix, Relay Therapeutics, Gilead, Sermonix and Novartis.
This publication has 61 references indexed in Scilit:
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerNew England Journal of Medicine, 2019
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialThe Lancet Oncology, 2017
- Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatmentClinical & Experimental Metastasis, 2016
- Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsCancer Research, 2016
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAAnnals of Oncology, 2014
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective studyNeuro-Oncology, 2014
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 studyThe Lancet Oncology, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Breast cancer subtypes and response to systemic treatment after whole‐brain radiotherapy in patients with brain metastasesCancer, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010